The US Food and Drug Administration’s back-to-back approvals of UCB S.A.’s Zilbrysq in myasthenia gravis and Bimzelx in psoriasis brought the Belgian company’s 2023 novel approval count to three, an impressive haul for a specialty company that propelled UCB into the front ranks of sponsors. But no-one is getting close to 2023 approvals standout Pfizer Inc., which notched its seventh and eighth novel clearances of the year with Velsipity.
Keeping Track: UCB’s Very Good Day, Pfizer’s Great Year
Pfizer adds Velsipity and Penbraya to its US FDA novel approval haul and UCB’s Bimzelx finally achieves FDA clearance, along with Zilbrysq.
More from US FDA Performance Tracker
• By
The 31 May goal date for Moderna’s next-generation COVID-19 vaccine looms over the month, but the US FDA's decision lineup includes three more novel agents, including AbbVie's Teliso-V antibody-drug conjugate, as well as supplemental indications like GSK's bid for Nucala in COPD.
• By
Antabio’s next-generation, broad-spectrum antibacterial, MEM-ANT3310, has made it onto the European Medicines Agency’s priority medicines scheme. The company says its product is designed to make a significant impact on the growing problem of antimicrobial resistance.
• By
Organizational turmoil has not yet affected reviews of novel agent applications, with Q1 2025 approvals coming in low, but the first quarter share of the entire year is variable.
• By
Sanofi’s Dupixent, Amgen’s Uplizna, and Bristol’s Opdivo seek new indications, while J&J hopes to start a franchise with nipocalimab and Stealth’s day of reckoning approaches.
More from Regulatory Trackers
• By
Organizational turmoil has not yet affected reviews of novel agent applications, with Q1 2025 approvals coming in low, but the first quarter share of the entire year is variable.
• By
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
• By
Sanofi’s Dupixent, Amgen’s Uplizna, and Bristol’s Opdivo seek new indications, while J&J hopes to start a franchise with nipocalimab and Stealth’s day of reckoning approaches.